Gels (Mar 2022)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma

  • Hui-Wen Chan,
  • Yi-Hsuan Lo,
  • Deng-Yuan Chang,
  • Jia-Je Li,
  • Wen-Yi Chang,
  • Chih-Hao Chen,
  • Chih-Hsien Chang,
  • Chuan-Lin Chen,
  • Hsin-Ell Wang,
  • Ren-Shyan Liu,
  • Chun-Yi Wu

DOI
https://doi.org/10.3390/gels8030180
Journal volume & issue
Vol. 8, no. 3
p. 180

Abstract

Read online

Transarterial radioembolization (TARE) is an emerging treatment for patients with unresectable hepatocellular carcinoma (HCC). This study successfully developed radiometal-labeled chitosan microspheres (111In/177Lu-DTPA-CMS) with a diameter of 36.5 ± 5.3 μm for TARE. The radiochemical yields of 111In/177Lu-DTPA-CMS were greater than 90% with high radiochemical purities (>98%). Most of the 111In/177Lu-DTPA-CMS were retained in the hepatoma and liver at 1 h after intraarterial (i.a.) administration. Except for liver accumulation, radioactivity in each normal organ was less than 1% of the injected radioactivity (%IA) at 72 h after injection. At 10 days after injection of 177Lu-DTPA-CMS (18.6 ± 1.3 MBq), the size of the hepatoma was significantly reduced by around 81%, while that of the rats in the control group continued to grow. This study demonstrated the effectiveness of 177Lu-DTPA-CMS in the treatment of N1-S1 hepatoma. 111In/177Lu-DTPA-CMS have the potential to be a superior theranostic pair for the treatment of clinical hepatoma.

Keywords